Ischemic Attack Articles & Analysis
5 news found
FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022. Asundexian is an investigational agent and has not been approved by any health authority for use in any country, for any indication. ...
ByBayer AG
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its ...
ByBayer AG
The primary efficacy endpoint was a composite of MALE and MACE, ie. acute limb ischemia, major amputation of a vascular etiology, heart attack (myocardial infarction, MI), ischemic stroke or cardiovascular death. ...
ByBayer AG
“The published results from our clinical trials to date [3], [4]. [5],[6], [7] have met our high expectations in showing the therapy’s ability to address the loss of heart function in ischemic heart failure. We look forward to completing our Phase III trial and engaging with the FDA as we move closer to the prospect of benefiting patients whose lives are severely ...
In the study, researchers identified ischemic strokes and transient ischemic attacks (TIA), sometimes called mini strokes but that often lead to a stroke later. Ischemic attacks are caused by a blockage of blood flow to the brain by a blood clot. ...